A medicine sample import application gets a decision in up to 5 working days. What to attach and how to justify the quantity
To import samples of medicines into Russia for clinical trials (CTs), regulatory review for registration, medicine development or scientific research, a legal entity applies to the Russian Ministry of Health (hereinafter the Ministry of Health) and obtains a conclusion. This follows from the Rules for Importing Medicines for Medical Use into the Russian Federation, approved by Resolution of the Government of the Russian Federation No. 853 of 1 June 2021 (hereinafter Resolution No. 853, the Importation Rules). Foreign medicine developers and manufacturers, persons acting on their instructions, scientific organizations, higher education institutions and medicine manufacturers import medicines for these purposes if they hold a conclusion, and the import of a specific batch proceeds on the basis of the conclusion.
Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (hereinafter 61-FZ) calls the same document a permit.
The application includes a justification of how many samples need to be imported. What the justification contains depends on the purpose of the import (under the Importation Rules as amended on 18 June 2025, in application from 27 June 2025). For registration and regulatory review, the documents named include calculations by the expert institution that conducts the regulatory review of the medicine.
The Ministry of Health reviews the application in no more than 5 working days from the date the documents are received (under 61-FZ and the Importation Rules). No fee is charged for issuing the conclusion. Under the Importation Rules, issued conclusions are valid indefinitely, while Decision of the EEC Board No. 45 of 16 May 2012 on the form of the conclusion says that the validity period of a conclusion is not subject to extension.
What applied under Resolution No. 771 and what changed
Import of medicine samples is governed by Resolution No. 853, in force since 1 September 2021. Before that date, Resolution of the Government of the Russian Federation No. 771 of 29 September 2010 «On the Procedure for Importing Medicines for Medical Use into the Territory of the Russian Federation» (hereinafter Resolution No. 771) applied. It ceased to be in force on 1 September 2021: Resolution No. 853 included it in the list of repealed acts. The last amending act indicated in the text of Resolution No. 771 is Resolution of the Government of the Russian Federation No. 1515 of 28 December 2016. Table 1 compares Resolution No. 771 in that version with the Importation Rules as amended on 18 June 2025. Changes made by Resolution of the Government of the Russian Federation No. 913 of 18 June 2025 (hereinafter Resolution No. 913) are marked in the table.
Table 1. What changed in the procedure for importing samples
| Issue | Before (Resolution No. 771) | Now (Resolution No. 853, as amended on 18 June 2025) |
|---|---|---|
| Name and form of the document for importing a batch | Permit of the Ministry of Health for importing a specific batch, in the form established by the Customs Union Commission | Conclusion issued by the Ministry of Health in accordance with Decision of the Board of the Eurasian Economic Commission (EEC) No. 45 of 16 May 2012 (hereinafter Decision No. 45) |
| Validity period of the import document | Stated in the permit | Issued conclusions are valid indefinitely |
| Filing the application | Application and its electronic copy in the manner established by the customs legislation of the Customs Union | The application is completed in the personal account on the Unified Portal of State and Municipal Services (EPGU) and sent to the Ministry of Health as an electronic document signed with an electronic signature, together with a set of electronic documents |
| Purposes of import by a foreign developer, a foreign manufacturer or a person acting on their instructions | Clinical trials, state registration of a medicinal product, inclusion of a pharmaceutical substance in the State Register of Medicines, quality control | The same purposes, plus medicine development, scientific and other research (amendment by Resolution No. 913), and registration and regulatory review of medicines for the common medicines market of the Eurasian Economic Union (EAEU) |
| Justification of quantity | Justification of the quantity of imported medicinal products and/or pharmaceutical substances, with no breakdown by purpose | The content of the justification is defined separately for development and scientific research, for CTs, and for registration and regulatory review (as amended by Resolution No. 913) |
| Documents on medicine quality | Quality certificate (certificate of analysis) issued by the manufacturing organization | Copies of quality documents issued by the manufacturer or another organization authorized to confirm quality under the legislation of the country of origin, with quality parameters and the manufacturing site |
| Applicant’s constituent documents | Copies of the applicant’s constituent and registration documents, including the charter; the Ministry of Health had no right to demand copies of the state registration certificate and the tax registration certificate | The charter is not in the list of documents; the applicant may attach copies of the certificates and the CT permit on its own initiative |
| Grounds for refusal | Incomplete or unreliable information; a ban on the medical use of the medicinal product in the territory of the Customs Union states | The same two grounds, with the ban determined for the territory of the EAEU, and a third ground for import under a Government act for a limited patient population |
| Register and information for customs | Applications and decisions are recorded in a register maintained by the Ministry of Health; the permit is presented to customs authorities | The Ministry of Health maintains a register of issued conclusions, which is for information only, and passes information from the conclusions to customs authorities weekly |
The 5-working-day period for reviewing the application, the absence of a fee and the ban on importing falsified, substandard and counterfeit medicines remained unchanged. Resolution No. 771 cannot be cited as a regulation in force.
Which act governs the import of samples and who files the application
The law permits the import of a specific batch of medicines on the basis of a permit from the authorized federal body and names the persons permitted to import (under 61-FZ). The procedure for obtaining the permit is set by the Importation Rules, which are in force until 1 September 2027.
The form of the conclusion was approved by Decision of the EEC Board No. 45 of 16 May 2012 «On the Unified Form of a Conclusion (Permit Document) for the Import, Export and Transit of Certain Goods Included in the Unified List of Goods to Which Non-Tariff Regulation Measures Apply in Trade with Third Countries, and on Methodological Guidelines for Completing It». The form has the lines «Issued to», «Name of goods», «Quantity», «Purpose of import (export)», «Basis» and «Conclusion valid until». An issued conclusion cannot be amended: if the details need to change, a new conclusion is issued and the previous one is cancelled. Two acts address the period of validity. Under Decision No. 45, the validity period of a conclusion is not subject to extension. Under the Importation Rules, issued conclusions are valid indefinitely.
A conclusion is requested by a legal entity. For samples for CTs, registration, regulatory review and development, these are:
a foreign medicine developer, a foreign medicine manufacturer or another legal entity acting on the developer’s instructions, if the import is for medicine development, scientific and other research, CTs, registration and regulatory review, inclusion of a pharmaceutical substance in the State Register of Medicines, or quality control;
a scientific organization, a higher education institution or a medicine manufacturer, if the import is for development, research, or control of the safety, quality and efficacy of medicines.
The Importation Rules name the purposes of import for which a conclusion is issued:
CTs: a specific batch of registered and/or unregistered medicines, which means a conclusion is needed also for a registered medicinal product if it is imported as a batch for a CT;
regulatory review and registration: a specific batch of unregistered medicines for regulatory review for registration, including registration on the common medicines market of the EAEU, state registration of a medicinal product and inclusion of a pharmaceutical substance in the State Register of Medicines;
medicine development, scientific and other research: a specific batch of unregistered medicines.
The quality of imported medicines is confirmed by the manufacturer’s certificate. The permit for import is presented to customs authorities when the medicines arrive in Russia. Importing falsified, substandard and counterfeit medicines is prohibited. Falsified and substandard medicines are seized and then destroyed or exported; counterfeit medicines are seized and destroyed. The person who carried out the import bears the costs.
The Importation Rules do not apply to:
narcotic drugs, psychotropic substances and their precursors included in Section 2.12 of the list of goods subject to a permit-based import procedure (approved by Decision of the EEC Board No. 30 of 21 April 2015) and in the list approved by Resolution of the Government of the Russian Federation No. 681 of 30 June 1998;
potent and poisonous substances from the nomenclature approved by Resolution of the Government of the Russian Federation No. 930 of 3 August 1996, if they are not precursors of narcotic drugs and psychotropic substances: they are imported under the procedure approved by Resolution of the Government of the Russian Federation No. 278 of 16 March 1996.
From 1 September 2026, the law permits one more type of import: samples (specimens) of medicines taken during pharmaceutical inspections for compliance with the requirements of the EAEU Good Manufacturing Practice rules (61-FZ as amended by Federal Law No. 324-FZ of 4 August 2026, hereinafter 324-FZ). The Importation Rules do not name such a purpose, and they do not describe the procedure for applying to import such samples.
What is checked in the application and how to justify the sample quantity
The applicant completes the application in the personal account on the EPGU. The application states the name of the medicinal product or pharmaceutical substance, dosage form, dose, concentration, packaging, manufacturer and country of manufacture.
The application is sent to the Ministry of Health as an electronic document signed with an electronic signature, together with a set of electronic documents:
a draft conclusion completed in the EPGU personal account;
a justification of the quantity of imported medicinal products and pharmaceutical substances;
a copy of the agreement (contract) with appendices and addenda or, if there is no agreement, a copy of another document confirming the intentions of the parties, if there are two or more parties;
copies of quality documents issued by the manufacturer or another organization authorized to confirm quality under the legislation of the country of origin, with quality parameters and the manufacturing site of the specific medicine;
for batches for CTs, copies of documents (packaging mock-ups or photographs) confirming the labeling under which the medicine can be used only in CTs.
The applicant may attach, on its own initiative, copies of the state registration certificate, the tax registration certificate and the Ministry of Health permit to conduct a CT, and the Ministry of Health may not demand them. If the copies are not attached, the Ministry of Health itself requests information about the legal entity from the Federal Tax Service and checks the CT permit against the register of issued permits.
The justification of quantity is determined by the purpose of the import (under the Importation Rules as amended on 18 June 2025). Table 2 gives the wording of the Importation Rules for each purpose.
Table 2. What the justification of the quantity of imported medicines consists of
| Purpose of import | Quantity is determined from | Justification is submitted as |
|---|---|---|
| Medicine development, scientific and other research | The needs of the ongoing preclinical study of the medicine under development and/or studies to establish the characteristics of the medicine during its development | A plan (protocol, program) of the study with the main objectives, methodology, procedures, statistical aspects, organization and resource planning; calculations of the quantity of the medicine for pharmacological and toxicological studies and/or for studies to establish the characteristics of the medicine (depending on the medicine, these are physicochemical properties, biological activity, immunochemical properties, purity and impurities, stability, impurity profile, degradation pathways, comparative dissolution kinetics); a document on the fact of development (an order, technical specification or program) |
| Clinical trials | The conditions of use of the medicinal product in the CT | Information on the regimen of use (description of the dosage form, packaging and labeling), doses, concentrations, frequency of intake or number of administrations, expected duration of subject participation, a description of the sequence and duration of all study periods, including the follow-up period if the protocol provides for it, and the number of patients; or other documents confirming the need to import the declared quantity |
| Registration and regulatory review of medicines | The need for the medicinal product for the in vitro comparative dissolution kinetics test (with justification of the number of buffer media and test replicates), the manufacturing process of the medicine, the manufacturing formula, or the material balance based on technological instructions or drafts of them | Extracts from technological instructions or drafts of them; extracts from normative documentation (normative document on quality, ND) or a draft of it, with the quantity of the medicine for quality tests by the corresponding parameters; references to pharmacopoeial monographs of the State Pharmacopoeia, the EAEU Pharmacopoeia or foreign pharmacopoeias; calculations by the expert institution that carries out the regulatory review of the medicine |
For registration and regulatory review, the Importation Rules name calculations by the expert institution that carries out the regulatory review of the medicine. The applicant’s own calculations are not named among the forms of justification for this purpose.
The Ministry of Health checks whether the information in the documents is complete and reliable and decides whether to issue the conclusion or refuse with reasons. The conclusion or the notice of refusal arrives in the applicant’s personal account as an electronic document signed with a qualified electronic signature.
A refusal can be based on two grounds: the applicant’s documents contain incomplete or unreliable information, or the medicine is banned for medical use in the territory of the EAEU. The third ground applies to import under a Government act for a limited patient population. After a refusal, the applicant can remove the reasons and file the documents again.
How many samples to request from the expert organization
The volume of materials for testing is set by the Rules for Registration and Regulatory Review of Medicines for Medical Use, approved by Decision of the EEC Council No. 78 of 3 November 2016 (hereinafter the Registration Rules, as amended on 26 November 2025). The Registration Rules distinguish two procedures: mutual recognition and the decentralized procedure.
Samples of the medicinal product, reference standards of active pharmaceutical ingredients and related impurities, specific reagents and other materials for testing are submitted as agreed with the expert organization. Samples of the medicinal product, specific reagents and other materials are supplied in a quantity that is agreed with the expert organization and is sufficient for no more than a triplicate analysis.
The quantity is calculated as follows:
under mutual recognition: in accordance with the requirements of the ND or other specifications included in the registration dossier;
under the decentralized procedure: in accordance with the requirements of the ND.
The authorized body (the expert organization) agrees the delivery deadline. This period is not included in the overall period for regulatory review and registration.
Before filing a registration application, the expert organization or the authorized body of an EAEU member state is entitled, at the applicant’s request, to hold a pre-registration consultation, including on whether samples of the medicinal product, reference standards, materials, specific reagents and consumables are needed for the laboratory quality review.
Samples, reagents and other materials are not required if testing at the expert organization is impossible because of:
limited availability of the materials, including where they are classified as orphan, high-tech, radiopharmaceutical, narcotic or psychotropic medicinal products, or medicinal products for treating high-cost nosologies because of their high price;
the impossibility of meeting the conditions for transport to the territory of the member state and/or for storage;
the absence of specialized equipment and consumables at the expert organization;
other reasons that the authorized body (the expert organization) determines in force majeure circumstances or circumstances beyond the parties’ control, including because of the specific features of manufacturing and quality control of the medicinal product.
In these cases, laboratory tests are carried out in the quality control laboratory of the medicinal product’s manufacturer or in a contract laboratory that the manufacturer uses, in the presence of representatives of the expert organization. The samples of the medicinal product intended for registration, reference standards, and medicinal products for preclinical and clinical studies are not subject to registration.
Which deadlines apply when importing samples
Table 3 collects the deadlines of the Importation Rules and the Registration Rules that affect the supply of samples. The Registration Rules set the deadlines for handling a request from the expert organization separately for mutual recognition and for the decentralized procedure.
Table 3. Deadlines for importing samples and handling a request from the expert organization
| Stage | Deadline | Source |
|---|---|---|
| Review of the application by the Ministry of Health | No more than 5 working days from the date the documents are received | 61-FZ; Importation Rules |
| Validity of an issued conclusion | Indefinite | Importation Rules |
| Transfer by the Ministry of Health of information on conclusions to customs authorities | Weekly, no later than the first working day of the calendar week | Importation Rules |
| Supply of samples to the expert organization | Within the period agreed by the authorized body (the expert organization); not included in the period for regulatory review and registration | Registration Rules |
| Applicant’s response to a request from the expert organization under mutual recognition | No more than 90 working days from receipt of the request; on the applicant’s justification the period can be extended, and the total period for responses to requests is no more than 180 working days | Registration Rules |
| Applicant’s receipt of a request from the expert organization under mutual recognition | On expiry of 1 working day from the date it was sent | Registration Rules |
| Time for preparing the response to a request under mutual recognition | Not included in the period for regulatory review and registration | Registration Rules |
| Notice to the applicant that the regulatory review is terminated under mutual recognition if no response is submitted | Within 14 working days from the date the decision is made | Registration Rules |
| Applicant’s response to a request under the decentralized procedure | No more than 90 working days; at the applicant’s request the authorized body of the reference state can extend the period, and the total maximum period for responses to requests is no more than 180 working days | Registration Rules |
| Time for preparing the response to a request under the decentralized procedure | Not included in the periods for regulatory review and registration | Registration Rules |
| Notice to the applicant that the regulatory review is terminated under the decentralized procedure if no response is submitted | Within 14 working days from the date the decision is made | Registration Rules |
The Ministry of Health transfers information on conclusions to customs authorities in electronic form through the unified system of interdepartmental electronic interaction. A conclusion is issued for a specific batch. The provisions of the Registration Rules on samples and on requests from the expert organization set no separate deadline for importing an additional batch of samples.
What to do
Identify the applicant and the purpose of the import. Check the organization against the list of persons whom the Importation Rules permit to import, and the purpose of the import against the purposes in the Importation Rules: the content of the quantity justification depends on the purpose (Table 2).
Request a pre-registration consultation from the expert organization.
In the request, ask it to state in writing:
the list of samples of the medicinal product, reference standards, reagents and consumables, with the quantity of each item and the basis of calculation (ND parameters, number of replicates, no more than a triplicate analysis under the Registration Rules);
the delivery deadline that the expert organization will set;
the items that the expert organization will accept without import, with tests at the manufacturer (under the Registration Rules).
Assemble the set of documents under the Importation Rules. Check the set: draft conclusion, justification of the quantity (for registration and regulatory review it includes calculations by the expert institution), the agreement or another document on the intentions of the parties, quality documents stating the manufacturing site, and, for batches for CTs, mock-ups or photographs of packaging with labeling for studies.
File the application through the EPGU. The Ministry of Health decides in no more than 5 working days. After a refusal, remove the reason and file the documents again. When you receive the conclusion, check all its lines, including «Conclusion valid until»: an issued conclusion cannot be amended, and if needed a new one is issued (under the methodological guidelines to Decision No. 45).
Plan the delivery with customs and the regulatory review period in mind. Send the samples after you receive the conclusion: the Ministry of Health passes information about it to customs once a week, and when the medicines arrive in Russia the permit is presented to customs authorities. Agree the delivery deadline for the samples with the expert organization. Under mutual recognition, the period for responding to a request from the expert organization runs from receipt of the request, that is, 1 working day after it is sent. Under the decentralized procedure, separate provisions of the Registration Rules apply; they are shown in Table 3.
What happens after 1 September 2027
The Importation Rules are in force until 1 September 2027. The Russian Ministry of Health has prepared a draft Government resolution with new Importation Rules, published for public discussion on regulation.gov.ru (draft No. 170856). According to a ppt.ru report of 8 September 2026, the new rules would replace the 2021 rules and apply from 1 September 2027 to 1 September 2033 if the draft is adopted. Until a new act is adopted, the procedure of Resolution No. 853 remains in force.
Regulatory framework:
1. Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (as amended on 4 August 2026)
2. Federal Law No. 324-FZ of 4 August 2026 «On Amendments to the Federal Law ‘On the Circulation of Medicines’ and Certain Legislative Acts of the Russian Federation»
3. Resolution of the Government of the Russian Federation No. 853 of 1 June 2021 «On Approval of the Rules for Importing Medicines for Medical Use into the Russian Federation and on Recognizing Certain Acts and Certain Provisions of Certain Acts of the Government of the Russian Federation as Repealed» (as amended on 18 June 2025)
4. Decision of the EEC Council No. 78 of 3 November 2016 «On the Rules for Registration and Regulatory Review of Medicines for Medical Use» (as amended on 26 November 2025)
5. Decision of the EEC Board No. 45 of 16 May 2012 «On the Unified Form of a Conclusion (Permit Document) for the Import, Export and Transit of Certain Goods Included in the Unified List of Goods to Which Non-Tariff Regulation Measures Apply in Trade with Third Countries, and on Methodological Guidelines for Completing It» (as amended by Decisions of the Board No. 114 of 4 September 2017 and No. 15 of 7 February 2023)
6. Resolution of the Government of the Russian Federation No. 913 of 18 June 2025 «On Amendments to Resolution of the Government of the Russian Federation No. 853 of 1 June 2021»
7. Decision of the EEC Board No. 30 of 21 April 2015 «On Non-Tariff Regulation Measures», Resolution of the Government of the Russian Federation No. 681 of 30 June 1998 «On Approval of the List of Narcotic Drugs, Psychotropic Substances and Their Precursors Subject to Control in the Russian Federation», Resolutions of the Government of the Russian Federation No. 930 of 3 August 1996 and No. 278 of 16 March 1996 (named in the Importation Rules; the texts were not used)
8. Resolution of the Government of the Russian Federation No. 771 of 29 September 2010 «On the Procedure for Importing Medicines for Medical Use into the Territory of the Russian Federation» (ceased to be in force on 1 September 2021; the last amending act in the text: Resolution of the Government of the Russian Federation No. 1515 of 28 December 2016)